Table 2.
Laboratory parameters of total cohort and subcohorts with and without thromboembolic events
| Cohort (N = 40) | Thromboembolic event | ||||||
|---|---|---|---|---|---|---|---|
| Yes (N = 23) | No (N = 17) | ||||||
| Median | [IQR] | Median | [IQR] | Median | [IQR] | p value | |
| Laboratory variables (normal values) | |||||||
| Haemoglobin (12·5–17·2 g/dL) | 10.1 | [8.5–11.2] | 9.70 | [8.3–10.8] | 10.4 | [9.3–11.9] | ns |
| White blood cells (3·5–10·5/nl) | 10.13 | [7.5–13.7] | 10.63 | [7.4–16] | 9.58 | [6.6–12.1] | ns |
| Platelet count (150–370/nl) | 193.5 | [131.3–316.3] | 181 | [116–306] | 209 | [178–325.5] | ns |
| Prothrombin time (70–130%) | 74.5 | [62.8–86] | 79 | [61–83] | 71 | [63.5–87.5] | ns |
| INR (0·9–1·25) | 1.2 | [1.1–1.4] | 1.18 | [1.1–1.4] | 1.26 | [1.1–1.4] | ns |
| PTT (26–40 s) | 45.65 | [39.4–56.1] | 51.10 | [40.8–57.4] | 41.1 | [38.7–54.2] | ns |
| Fibrinogen (1·6–4 g/l) | 6.67 | [4.7–7.7] | 6.72 | [5.0–7.8] | 6.1 | [4.6–7.9] | ns |
| D-dimers (< 0·5 mg/l) | 3.95 | [2.6–5.9] | 4.84 | [3.5–7.2] | 3.06 | [2.3–3.9] | 0.003 |
| max. D-dimers (< 0·5 mg/l) | 8.25 | [3.6–16.2] | 11.57 | [8.2–18.4] | 3.98 | [2.6–6.4] | < 0.001 |
| Procalcitonin (0·5 µg/l) | 0.57 | [0.2–2.5] | 0.81 | [0.4–4.7] | 0.24 | [0.2–1.3] | ns |
| CRP (< 0·5 mg/l) | 123.8 | [84.3–216.5] | 130 | [86–273.7] | 111 | [79.3–185] | ns |
| max. CRP (< 0·5 mg/l) | 312.9 | [208.3–343.9] | 341.4 | [261.1–370.7] | 261.05 | [175.3–312.9] | 0.002 |
| IL-6 (< 7 ng/l) | 103 | [35·6–230] | 88 | [27.7–340] | 153 | [53.7–206.5] | ns |
| max. IL-6 (< 7 ng/l) | 558.6 | [178.8–1792.3] | 550 | [174–2475] | 567.2 | [186.5–1196.5] | ns |
| Ferritin (30–400 µg/l) | 1636 | [1067.8–4028.5] | 1663 | [1218.5–4655] | 1567 | [720–3662] | ns |
| max. Ferritin (30–400 µg/l) | 2523.2 | [1536.7–6635.1] | 2781.5 | [1854.7–7996.2] | 2028.4 | [922.9–4893.4] | ns |
| tPA (2–8 µg/l) | 1 | [0.9–5.5] | 1 | [0.9–3.6] | 2 | [0.9–9.9] | ns |
| PAI-1 (7–43 ng/ml) | 36 | [17–70] | 31 | [12–61] | 42.50 | [25.3–87] | ns |
| tPA/PAI-1 | 0.053 | [0.02–0.18] | 0.05 | [0.02–0.14] | 11 | [0.03–0.24] | ns |
| Antithrombin III (80–120%) | 79 | [58.5–96.5] | 75.5 | [56.8–84] | 94 | [66.5–110] | ns |
| Factor VIII (50–150%) | 258 | [190.5–319.5] | 260 | [219.5–355] | 222 | [149.5–289.5] | ns |
| Plasminogen (80–120%) | 88 | [72.8–114] | 82 | [72.8–109.8] | 101 | [70.8–129.8] | ns |
| ROTEM variables | |||||||
| FIBTEM CT (s) | 88.5 | [78–97.8] | 89 | [78–102] | 88 | [75.5–96] | ns |
| FIBTEM CFT (s) | 68 | [51–104] | 64.5 | [54–95.8] | 71 | [47–165] | ns |
| FIBTEM MCF (mm) | 34.5 | [27.3–39.5] | 35 | [27–38] | 34 | [27–40] | ns |
| EXTEM CT (s) | 86 | [69.5–99.8] | 84 | [69–96] | 86 | [70.5–107.5] | ns |
| EXTEM CFT (s) | 46.5 | [40–60.5] | 47 | [40–61] | 45 | [40.5–56.5] | ns |
| EXTEM MCF (mm) | 75 | [70.3–78] | 75 | [69–78] | 76 | [72.5–78.5] | ns |
| INTEM CT (s) | 208 | [181.3–227.5] | 215 | [197–251] | 189 | [171.5–212] | 0.005 |
| INTEM CFT (s) | 50.5 | [39.5–61.8] | 56 | [39–63] | 45 | [39.5–60.5] | ns |
| INTEM MCF (mm) | 74 | [69–77] | 74 | [65–77] | 73 | [69.5–78] | ns |
| HEPTEM CT (s) | 188.5 | [170.5–208.3] | 193 | [173–209] | 173 | [159–206] | ns |
| HEPTEM CFT (s) | 41 | [35.5–56.5] | 40 | [34–60] | 42 | [37–51] | ns |
| HEPTEM MCF (mm) | 73 | [67.5–75.3] | 73 | [66–76] | 71 | [71–75] | ns |
| ML, EXTEM (%) | 3 | [1.3–5.8] | 3 | [0–5] | 5 | [3.5–8] | 0.001 |
| ML, INTEM (%) | 3 | [1–6] | 2 | [0–3] | 6 | [2.5–6] | 0.001 |
Unless values are designated as maximum values during the ICU stay, these parameters were determined on the day, when ROTEM analysis was performed, after admission to our ICUs
CT clotting time, CFT clot formation time, MCF maximum clot firmness, ML maximum lysis